Reduction of Extramedullary Complications in Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome Treated With Azacitidine. Issue 3 (April 2020)

• Record Type: Journal Article
• Authors: Shabanova, Iren; Cada, Michaela; Johnston, Donna L.; Abbott, Lesleigh S.; Leung, Elaine W.; Schechter, Tal; Dror, Yigal; Klaassen, Robert J.
• Is Part Of: Journal of pediatric hematology/oncology. Volume 42:Issue 3(2020)
• Publication Date: 2020-04
• Subjects: myelodysplastic syndrome -- Shwachman-Diamond syndrome -- treatment -- azacitidine -- extramedullary -- monosomy 7; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000001763
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : The distinction between myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) often relies on an arbitrary marrow blast cutoff of 30% in pediatrics and 20% in adults. There is little data about the treatment of children with extramedullary myeloid malignancy that has features of both, MDS and AML. Herein, we report for the first time 2 patients MDS/AML (1 with Shwachman-Diamond syndrome and 1 with idiopathic MDS and monosomy 7) who presented with extramedullary complications, received treatment with azacitidine, achieved complete remission and subsequently underwent hematopoietic stem cell transplantation.